Halozyme Therapeutics Inc. (HALO)
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade)
Halozyme is upgraded to a near-term Buy, driven by robust 2025–2028 royalty visibility and conservative valuation. HALO's acquisition of Elektrofi (Hypercon) extends IP into the 2040s, offering optionality but with uncertain long-term revenue durability. ENHANZE's U.S. patent expiry in 2027 raises post-2030 questions, but royalty streams and asset-light margins remain strong near-term.
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript
What Makes Halozyme Therapeutics (HALO) a New Buy Stock
Halozyme Therapeutics (HALO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.63 per share. This compares to earnings of $1.27 per share a year ago.
Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. ( HALO ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President, CEO & Director Nicole LaBrosse - Senior VP & CFO Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Adam Ferrari - JPMorgan Chase & Co, Research Division Mitchell Kapoor - H.C. Wainwright & Co, LLC, Research Division Brendan Smith - TD Cowen, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Presentation Operator Good afternoon.
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
